The Role of Novel Targeted Therapies

EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer

EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer

EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer

EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer

EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer

EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing

EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer

Now Viewing

EP: 8.The Role of Novel Targeted Therapies

EP: 9.The Use of PARP Inhibitors in Ovarian Cancer

EP: 10.Earlier Introduction of Antibody-Drug Conjugates

EP: 11.Approaching Treatment Sequencing In Heavily Pretreated Patients

EP: 12.Single-Agent Vs Combination Regimens

EP: 13.The Potential Impact of Investigational Therapies

EP: 14.Learnings From Key Clinical Trials in Ovarian Cancer

EP: 15.Overcoming Payer-Related Barriers for Optimal Care in Patients With Ovarian Cancer

EP: 16.The Importance of Multidisciplinary Collaboration in the Management of Ovarian Cancer

EP: 17.Streamlining Biomarker-Driven Therapy Decisions to Prevent Delays

EP: 18.The Effect of Adverse Event Profiles on Treatment Decisions

EP: 19.Evaluating Long-Term Safety Considerations for Targeted Therapies in Ovarian Cancer

Video content is prompted by the following:

Novel Targeted Therapies in the Treatment Landscape

Key Themes:

• Emergence of antibody-drug conjugates (ADCs) targeting various receptors
• Movement of ADCs into earlier treatment settings
• Biomarker-directed therapy approach

Notable Insights:

• Multiple ADCs are in development with different targeting mechanisms and payloads:
  • Mirvetuximab soravtansine (folate receptor alpha, microtubule toxin)
  • Renatabart cecitakin (folate receptor alpha, exatecan payload)
  • Trastuzumab deruxtecan (HER2, deruxtecan payload)
  • Relutagimod deruxtecan (cadherin-6, deruxtecan payload)
  • TORL-1-23 (claudin-6, MMAE payload)
• ADCs are moving from platinum-resistant settings into maintenance therapy and frontline treatment:
  • GLORIOSA trial: mirvetuximab plus bevacizumab maintenance after second-line platinum
  • Trastuzumab deruxtecan trials in HRD-negative frontline maintenance
• Dr Moore emphasized that these are “very effective medications” but acknowledged: “We’re excited, but there’s a lot we have to learn...there’s just going to be quite a bit of work to do in the next years to really sort this out, to optimize for patients.”